AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hosp...(were 20 appendectomies of which 14were p...),Health

Date:9/28/2007

were 20 appendectomies of which 14 were pathology-confirmed appendicitis cases, and 6 unnecessary surgeries. The AppyScore screen test results correctly identified all 14 appendicitis cases and could have avoided 4 of the 6 (66%) unnecessary appendectomy surgeries in this group of children.

Appendicitis diagnosis issues in females. Appendicitis diagnostic errors are far more common in females than in males. For example, the misdiagnosis of women of reproductive age (aged 14 to 49) for unnecessary appendicitis surgery can range from 20% to 45% (Morse et al., 2007 Am Surg vol 73, no 6: pp 580-4). In the AspenBio study, there were a total of 198 evaluable female patients, of which 42 had pathology confirmed appendicitis. The AppyScore screen test identified 41/42 (98%) of these pathology-confirmed appendicitis cases. There were 109 female patients 30 years of age and younger out of the 198 evaluable female patients. Of these younger female patients there were 30 appendectomies performed with only 20 subsequently confirmed by pathology to have true appendicitis. That means 10 patients (30%) experienced unnecessary surgeries in this age group. The AppyScore screen test correctly identified all 20 appendicitis cases and could have prevented 6 of the 10 unnecessary surgeries that were performed in this group. (Although these observations were applicable to this female population, it should be noted that statistically the accuracy of AppyScore was generally the same regardless of gender.)

Benefits of positive AppyScore test results in non-appendicitis patients. Based on our study, patients with a positive AppyScore have a higher likelihood (p < 0.0001) of having a diagnosis of appendicitis or other medical condition because 72% (161/223) of the AppyScore positive patients were given a disease diagnosis as compared with only 43% (38/88) in the AppyScore negative patients. Of the total patients receiving CTs there were 120 evaluable patients whose CT was consider
'/>"/>

SOURCE AspenBio Pharma, Inc. Copyright©2007 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis